Cholesterol and mevalonic acid modulation in cell metabolism and multiplication

Soma, Maurizio R.; Corsini, Alberto; Paoletti, Rodolfo

doi:10.1016/0378-4274(92)90167-i

Cited by 75 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The intermediates of mevalonate pathway are essential for different cellular functions. Statins reduce not only cholesterol levels but also mevalonate synthesis and the production of dolichol, GPP, and FPP, as well as tumor cell growth in vitro and in vivo (Soma et al, 1992). Primary N-Rasmutated acute myeloid leukemia (AML) cells were less sensitive to simvastatin than nonmutated AML cells, suggesting a Ras signaling-independent inhibition of cell proliferation (Clutterbuck et al, 1998).…”

Section: A Effects Of Statins In Cancermentioning

confidence: 99%

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Gazzerro

Proto²,

Gangemi³

et al. 2011

Pharmacol Rev

398

370

View full text Add to dashboard Cite

Section: A Effects Of Statins In Cancermentioning

confidence: 99%

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Gazzerro

Proto²,

Gangemi³

et al. 2011

Pharmacol Rev

398

370

View full text Add to dashboard Cite

“…Statins inhibit dolichol, GPP and FPP production, and block tumor cell growth in vitro and in vivo [48]. For example, lovastatin has been shown to stabilize the cell cycle kinase inhibitors p21 and p27, and to arrest breast cancer cell lines in the G 1 phase of the cell cycle [49].…”

Section: Inhibition Of Tumor Cell Growthmentioning

confidence: 99%

The Role of Statins in Cancer Therapy

Cleeland²,

et al. 2006

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. Explain how statins, used in the treatment of hypercholesterolemia, may be applicable to cancer prevention.2. Discuss how statins potentially interfere with biologic processes relevant to cancer etiology. AbstractAdministration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically, statins have been shown to exert several beneficial antineoplastic properties, including decreased tumor growth, angiogenesis, and metastasis. The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed. The Oncologist 2006;11:306-315

show abstract

“…1 Statins reduce cholesterol biosynthesis in the liver by interfering with the mevalonate pathway and inhibiting HMGCR. In addition to cholesterol, this pathway produces isoprenoids, which are necessary for regulation of cell growth and oncogene expression, [2][3][4][5][6][7][8][9] while cholesterol is a critical component of intracellular lipid rafts, which are pivotal for intracellular signaling. 9 Apart from their role as lipid-lowering agents, they have been found to have immunomodulatory and antineoplastic effects.…”

Section: Introductionmentioning

confidence: 99%

Statins and risk of breast cancer recurrence.

Sakellakis

Kostaki

Akinosoglou

et al. 2016

JCO

View full text Add to dashboard Cite

Background:The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods:We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapsefree survival (16.6 vs 10.2 years, P=0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, P=0.006). Conclusion: Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups.

show abstract

Cholesterol and mevalonic acid modulation in cell metabolism and multiplication

Cited by 75 publications

References 26 publications

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

The Role of Statins in Cancer Therapy

Statins and risk of breast cancer recurrence.

Contact Info

Product

Resources

About